ADAM TRAN: Open Payments
NPI 1700591484 · MISSION VIEJO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,738 in 174 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $2,655 · 2025 $4,738
Food & beverage: $4,727Education: $11
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 26 | $932 |
| ABBVIE INC. | 25 | $551 |
| Vanda Pharmaceuticals Inc. | 17 | $533 |
| Neurocrine BioSciences, Inc. | 14 | $511 |
| Otsuka America Pharmaceutical, Inc. | 13 | $437 |
| Teva Pharmaceuticals USA, Inc. | 16 | $381 |
| E.R. Squibb & Sons, L.L.C. | 10 | $305 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $240 |
| Axsome Therapeutics, Inc. | 9 | $199 |
| Alkermes, Inc. | 10 | $168 |
Products named: VRAYLAR, INGREZZA, SPRAVATO, FANAPT, INVEGA SUSTENNA, REXULTI, AUSTEDO XR, COBENFY.
Industry payments across CA — which companies pay providers there.
